Efficacy News and Research

RSS

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

The U.S. Food and Drug Administration today approved Dificid tablets for the treatment of Clostridium difficile-associated diarrhea.

30 May 2011

Efficacy of Abbott cholesterol drug in question

A latest study has found that using medication to raise good cholesterol while lowering the bad does NOT translate into fewer adverse cardiovascular events like heart attacks and strokes. The study was revealed Thursday by the National Institutes of Health and it found that high dosages of Abbott Laboratories' Niaspan failed to prevent heart attacks and boosted the likelihood of a stroke when combined with the popular generic cholesterol pill Simvastatin, also known under the brand name Zocor.

29 May 2011

D3 Oncology Solutions provides six-month free trial period for Via Oncology Pathways program

D3 Oncology Solutions today announced that it will provide its Via Oncology Pathways for a six-month free trial period to enable cancer programs to align the timing of their investment with a strategy for sharing potential savings with payors and other key stakeholders.

27 May 2011

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular events, including heart attacks and stroke.

27 May 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

CEL-SCI Corporation today announced the positive results of efficacy studies in mice of L.E.A.P.S.TM H1N1 activated dendritic cells to treat the H1N1 virus.

27 May 2011

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Neurologix, Inc. announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease.

27 May 2011

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

MAP Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults.

27 May 2011

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

BioCryst Pharmaceuticals, Inc. presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, U.K.

26 May 2011

Study evaluates effectiveness of systems training for emotion control in 'real world' patients with BPD

A study published in the current issue of Psychotherapy and Psychosomatics evaluates the effectiveness of systems training for emotion control in "real world" patients with borderline personality disorder.

26 May 2011

New Hypertension Management Program study results revealed at ASH scientific meeting

High blood pressure - the silent killer - is taking a hit from a new, ground-breaking treatment program from the Heart and Stroke Foundation of Ontario.

26 May 2011

Tofacitinib safe and effective for patients with rheumatoid arthritis

Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.

26 May 2011

Precision ophthalmic tint lenses reduce migraine, study shows

Precision tinted lenses have been used widely to reduce visual perceptual distortions in poor readers, and are increasingly used for migraine sufferers, but until now the science behind these effects has been unclear.

26 May 2011

Recent advances in vaccine development for malaria, TB and HIV/AIDS

Collectively, malaria, TB & HIV/AIDS cause more than five million deaths per year - nearly the entire population of the state of Washington - and represent one of the world's major public health challenges as we move into the second decade of the 21st century.

26 May 2011

Scarcity of resources calls for equitable distribution system for novel HCV treatment

For many patients with the hepatitis C virus, direct antiviral agents (DAA) offer a potential cure for the disease. The Food and Drug Administration (FDA) has recently approved two new DAAs, telaprevir and boceprevir, and with that clinicians must now decide who should be the first to receive this treatment.

25 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

FDA grants approval for CSI to complete enrollment in ORBIT II IDE coronary clinical trial

Cardiovascular Systems, Inc. has received FDA approval to complete enrollment of 429 patients in its ORBIT II Investigational Device Exemption clinical trial for a coronary application for its Diamondback 360 System.

25 May 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Positive interim results from new bladder cancer therapy trial

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

25 May 2011

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

There's a wealth of health information hiding in the human immune system. Accessing it, however, can be very challenging, as the many and complex roles that the immune system plays can mask the critical information that is relevant to addressing specific health issues.

25 May 2011

Efficacy News and Research

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

Efficacy of Abbott cholesterol drug in question

D3 Oncology Solutions provides six-month free trial period for Via Oncology Pathways program

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

Study evaluates effectiveness of systems training for emotion control in 'real world' patients with BPD

New Hypertension Management Program study results revealed at ASH scientific meeting

Tofacitinib safe and effective for patients with rheumatoid arthritis

Precision ophthalmic tint lenses reduce migraine, study shows

Recent advances in vaccine development for malaria, TB and HIV/AIDS

Scarcity of resources calls for equitable distribution system for novel HCV treatment

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

FDA grants approval for CSI to complete enrollment in ORBIT II IDE coronary clinical trial

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Positive interim results from new bladder cancer therapy trial

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News